Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg lymphoma biomarker consortium

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 805-812

  De Jong, Daphne ^a   Rosenwald, Andreas ^b   Chhanabhai, Mukesh ^b   Gaulard, Philippe ^b   Klapper, Wolfram ^b   Lee, Abigail ^b   Sander, Birgitta ^b   Thorns, Christoph ^b   Campo, Elias ^b   Molina, Thierry ^b   Norton, Andrew ^b   Hagenbeek, Anton ^b   Horning, Sandra ^b   Lister, Andrew ^b   Raemaekers, John ^b   Gascoyne, Randy D ^b   Salles, Gilles ^b   Weller, Edie ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIBODY; CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN BCL 6; BCL6 PROTEIN, HUMAN; CD5 ANTIGEN; DNA BINDING PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CANADA; CLINICAL ARTICLE; EUROPE; EVALUATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STAINING; TISSUE MICROARRAY; UNITED STATES; CHEMISTRY; CLASSIFICATION; IMMUNOLOGY; LARGE CELL LYMPHOMA; METHODOLOGY;

ANTIGENS, CD5; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; NEPRILYSIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947538494     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.4490     Document Type: Article

References (29)

1. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
2. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
3. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
4. Feuerhake F, Kutok JL, Monti S, et al: NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106:1392-1399, 2005
5. Barrans SL, Carter I, Owen RG, et al: Germinal center phenotype and bcl-2 expression combined with International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143, 2002
6. Colomo L, Lopez-Guillermo A, Perales M, et al: Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101:78-84, 2003
7. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
8. Chang CC, McClintock S, Cleveland RP, et al: Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464-470, 2004
9. de Paepe P, Achten R, Verhoef G, et al: Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathological entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 23:1-9, 2005
10. Berglund M, Thunberg U, Amini R-M, et al: Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18:1113-1120, 2005
11. Zinzani PL, Dirnhofer S, Sabatini E, et al: Identi-fication of outcome predictors in diffuse large B-cell lymphoma: Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue microarrays. Haematologica 90:341-347, 2005
12. Kramer MH, Hermans J, Parker J, et al: Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 14:2131-2138, 1996
13. Hill ME, MacLennan KA, Cunningham DC, et al: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 88:1046-1051, 1996
14. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265-272, 1996
15. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
16. Iqbal J, Sanger WG, Horsman DE, et al: Bcl-2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165:159-166, 2004
17. Lossos IS, Jones CD, Warnke R, et al: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98:945-951, 2001
18. Adida C, Haioun C, Gaulard P, et al: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921-1925, 2000
19. Sagaert X, de Paepe P, Libbrecht L, et al: Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24:2490-2497, 2006
20. Banham AH, Connors JM, Brown PJ, et al: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072, 2005
21. Barrans SL, Fenton JA, Banham A, et al: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935, 2004
22. Kersten MJ, de Jong D, Raemaekers J, et al: Beyond the International Prognostic Index: New prognostic factors in follicular lymphoma and diffuse large-cell lymphoma - A meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J 5:202-208, 2004
23. Woolson RF, Clarke WR: Statistical Methods for the Analysis of Biomedical Data. New York, NY, Wiley, 2002
24. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, NY, Chapman & Hall, 1993
25. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003
26. Iqbal J, Neppalli VT, Wright G, et al: Bcl-2 expression is a prognostic marker for activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24:961-968, 2006
27. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006
28. Moskowitz CH, Zelenetz AD, Kwealramani T, et al: Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 106:3383-3385, 2005
29. Oschlies I, Klapper W, Zimmerman M, et al: Diffuse large B-cell lymphoma in paediatric patients predominantly belong to the germinal-center type B-cell lymphomas. Blood 107:4047-4052, 2006